论文部分内容阅读
目的观察替吉奥治疗老年晚期消化道恶性肿瘤的近期临床效果和不良反应发生情况。方法 68例老年晚期消化道恶性肿瘤患者,随机分成替吉奥组(33例)和对照组(35例)。替吉奥组采用替吉奥胶囊(S-1)单药口服治疗,对照组采用FOLFOX4方案化疗。比较两组的近期疗效及不良反应情况。结果两组所有病例均获得随访,替吉奥组总有效率(ORR)为27.3%,疾病控制率(DCR)为57.6%;对照组ORR为22.9%,DCR为31.4%;两组ORR比较差异无统计学意义(P>0.05);替吉奥组DCR高于对照组,差异具有统计学意义(P<0.05)。替吉奥组中位生存期为32周,对照组中位生存期为27周,两组比较差异具有统计学意义(P<0.01)。替吉奥组行为状态阳性率、体重阳性率分别为42.4%、27.3%,均高于对照组的17.1%、8.6%,差异均具有统计学意义(P<0.05)。对照组较替吉奥组白细胞减少明显,差异具有统计学意义(P<0.05);对照组恶心呕吐反应重于替吉奥组,差异具有统计学意义(P<0.05);两组其他不良反应情况比较差异无统计学意义(P>0.05)。两组均未发现血栓性静脉炎、浮肿等不良反应,且均无致命性不良反应。结论口服替吉奥治疗老年晚期消化道恶性肿瘤的近期疗效较好,且其更安全患者易接受。
Objective To observe the short-term clinical efficacy and side effects of TIGO in the treatment of elderly patients with advanced gastrointestinal malignancies. Methods Sixty-eight elderly patients with advanced gastrointestinal cancer were randomly divided into two groups: control group (n = 30) and control group (n = 35). The rabbits were used for the treatment of Gio capsules (S-1) alone and the control group were treated with FOLFOX4 chemotherapy. The two groups were compared the short-term efficacy and adverse reactions. Results All the cases were followed up. The total effective rate (ORR) was 27.3% and the disease control rate (DCR) was 57.6% in the two groups. ORR was 22.9% and DCR was 31.4% There was no statistical significance (P> 0.05). The DCR in treatment group was higher than that in control group (P <0.05). The median survival time was 32 weeks for the group of patients with a median of 27 weeks and the median survival time of the control group was 27 weeks. There was significant difference between the two groups (P <0.01). The positive rates of behavioral status and weight of the patients in the treatment group were 42.4% and 27.3%, respectively, which were significantly higher than those in the control group (17.1% and 8.6%, respectively) (P <0.05). (P <0.05). The nausea and vomiting of the control group was more severe than that of the control group (P <0.05). There was no significant difference in the other adverse reactions between the two groups The difference was not statistically significant (P> 0.05). No adverse reactions such as thrombophlebitis and edema were found in both groups, and no fatal adverse reactions were found. Conclusion Oral treatment of advanced gastrointestinal cancer for the elderly with good immediate effect, and its more safer patients acceptable.